On June 30, Definium Therapeutics rose 5.04% in regular trading, trading at $48.63 per share, with turnover of $22.16 million. The rally follows a cluster of positive catalysts in recent sessions.

On June 22, the company announced that its lead candidate DT120 orally disintegrating tablet achieved positive topline results in the pivotal Phase 3 EMERGE study for major depressive disorder, meeting its primary endpoint with statistically significant and clinically meaningful improvement over placebo. On June 26, Definium closed an upsized public offering of approximately 23.7 million common shares at $34 each, raising gross proceeds of $805 million, with underwriters exercising their overallotment option in full — reflecting strong institutional demand. Proceeds are earmarked for R&D, potential commercialization preparation for DT120 ODT, and general corporate purposes. Additionally, RBC Capital raised its price target from $36 to $57, maintaining an Outperform rating.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)